Latest Commercialisation News

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Ore Resources has completed its Phase 3 drilling at the Miriam Project, targeting extensions of high-grade gold lodes, with assay results expected in late January 2026. The company is well-funded and poised for an active exploration program in 2026.

Encounter Resources reports significant extensions of shallow, high-grade niobium mineralisation east of its Green Mineral Resource Estimate at the Aileron Project, with promising drill results and a major development program planned for 2026.

Elixir Energy has partnered with QGC to share 3D seismic data over a key Queensland gas permit, aiming to reduce risks ahead of the Daydream-3 appraisal well. This collaboration highlights the strategic importance of the Taroom Trough in Australia’s gas landscape.

Forrestania Resources has crossed the critical 50% acceptance threshold in its takeover of Kula Gold, signaling strong shareholder backing and advancing its regional consolidation strategy in Western Australia's gold belts.

Alexium International has acquired Microtek Laboratories’ microencapsulation and phase-change material business, backed by a $6.8 million entitlement offer to strengthen its manufacturing and innovation capabilities in the US.

HyTerra Limited has appointed Riley Kemp as its new CEO, aiming to accelerate growth and strengthen its position in the emerging geologic hydrogen sector.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.